Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Axsome Therapeutics's share price for the quarter that ended in Mar. 2026 was MXN1519. Axsome Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 51 Mil. Therefore, Axsome Therapeutics's market cap for the quarter that ended in Mar. 2026 was MXN78,107 Mil.
Axsome Therapeutics's quarterly market cap
increased
from Sep. 2025 (MXN76,418 Mil) to Dec. 2025 (MXN77,291 Mil) and
increased
from Dec. 2025 (MXN77,291 Mil) to Mar. 2026 (MXN78,107 Mil).
Axsome Therapeutics's annual market cap
increased
from Dec. 2023 (MXN59,047 Mil) to Dec. 2024 (MXN73,927 Mil) and
increased
from Dec. 2024 (MXN73,927 Mil) to Dec. 2025 (MXN77,291 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Axsome Therapeutics's Enterprise Value for Today is MXN204,308 Mil.
Axsome Therapeutics (MEX:AZSM) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Axsome Therapeutics Market Cap Related Terms
Axsome Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for Axsome Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:AZSM vs MDGL, IONS, BMRN: Market Cap Comparison
For the Biotechnology subindustry, Axsome Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Axsome Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Axsome Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Axsome Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Axsome Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Axsome Therapeutics (MEX:AZSM) has a Market Cap of MXN205,801 Mil as of Jul. 14, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Axsome Therapeutics and its competitors. According to the industry distribution chart, Axsome Therapeutics ranks #28 out of 1423 companies in the Biotechnology industry, placing it in the top 2%.
Is Axsome Therapeutics' Market Cap too high?
Axsome Therapeutics' current Market Cap is MXN205,801 Mil. Based on the distribution chart, Axsome Therapeutics ranks #28 out of 1423 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Axsome Therapeutics has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Axsome Therapeutics' Market Cap compare to MDGL and IONS?
According to the Biotechnology industry distribution chart, Axsome Therapeutics ranks #28 out of 1423 companies for Market Cap. This places Axsome Therapeutics in the top 2% of its industry — outperforming the majority of peers. The industry median Market Cap is 115.88. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 115.88, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Axsome Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 115.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Axsome Therapeutics's current Market Cap is MXN205,801 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Axsome Therapeutics stock overvalued right now?
Axsome Therapeutics (MEX:AZSM) has a current Market Cap of MXN205,801 Mil. The stock's GF Value™ is MXN1,494.25, compared to a current price of MXN1,519.00 — trading 1.7% above its estimated fair value. The current Market Cap is MXN205,801 Mil. Axsome Therapeutics' overall GF Score™ is 52/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Axsome Therapeutics (MEX:AZSM), the current Market Cap is MXN205,801 Mil as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Axsome Therapeutics (MEX:AZSM) Overvalued in 2026?
Based on GuruFocus' analysis, Axsome Therapeutics stock appears to be overvalued.
The current stock price of MXN1,519.00 is trading 1.7% above its estimated GF Value™ of MXN1,494.25.
Key valuation signals for MEX:AZSM:
Market Cap: MXN205,801 Mil
GF Value™: MXN1,494.25 vs. price of MXN1,519.00 (1.7% above fair value)
No single metric tells the full story. See the MEX:AZSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
52GF Score
Get the complete analysis for MEX:AZSM
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:AZSM has been successfully added to your 
